Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/YCT.0000000000000224 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent COVID-19 symptoms and associated factors in a tertiary hospital in Thailand.
J Infect Dev Ctries
December 2024
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand.
Introduction: Coronavirus disease 2019 (COVID-19) is associated with long-term symptoms, but the spectrum of these symptoms remains unclear. We aimed to identify the prevalence and factors associated with persistent symptoms in patients at the post-COVID-19 outpatient clinic.
Methodology: This cross-sectional, observational study included hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients followed-up at a post-COVID-19 clinic between September 2021 and January 2022.
[Cancer and nutritional management of overweight and obesity: Practice evaluation].
Bull Cancer
January 2025
Département prévention cancer environnement, centre Léon-Bérard, 69008 Lyon, France; Inserm U1296 rayonnements : défense, santé, environnement, centre Léon-Bérard, 69008 Lyon, France.
Context: The aim of this practice evaluation was to assess weight trends during and after a nutritional intervention in cancer patients and survivors.
Methods: This retrospective study was conducted between January 2014 and October 2020 in adults with different cancer types managed at the Léon-Bérard Cancer Center, undergoing treatment or during post-treatment follow-up, with a BMI≥25kg/m and who had at least 3 consultations with a nutrition physician. Nutritional management focused on behavioral, metabolic and nutritional aspects.
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Lancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFBimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period.
Br J Dermatol
January 2025
Department of Dermatology, Yale University, New Haven, Connecticut, USA.
Background: Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody that targets both IL-17A and IL-17F.
View Article and Find Full Text PDFSocial connectedness in older adults: The potential of social internet use to maintain a strong and stable personal network.
J Gerontol B Psychol Sci Soc Sci
January 2025
Department of Geriatric Medicine, Radboud university medical center, Nijmegen, The Netherlands.
Objective: Maintaining a strong social network in later life can be challenging due to limited resources, life events, and changes in health. Social internet use provides an accessible way for communication that is less susceptible to age-related challenges. Although social internet use is increasingly used by older adults, we do not know how social internet use shapes older adults' offline networks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!